JP6980694B2 - 投与のための方法およびレシニフェラトキシンで心血管疾患を治療する方法 - Google Patents

投与のための方法およびレシニフェラトキシンで心血管疾患を治療する方法 Download PDF

Info

Publication number
JP6980694B2
JP6980694B2 JP2018553923A JP2018553923A JP6980694B2 JP 6980694 B2 JP6980694 B2 JP 6980694B2 JP 2018553923 A JP2018553923 A JP 2018553923A JP 2018553923 A JP2018553923 A JP 2018553923A JP 6980694 B2 JP6980694 B2 JP 6980694B2
Authority
JP
Japan
Prior art keywords
rtx
administration
group
resiniferatoxin
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018553923A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019511536A5 (enExample
JP2019511536A (ja
Inventor
アービング・エイチ・ズッカー
ハンジュン・ワン
Original Assignee
ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ filed Critical ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ
Publication of JP2019511536A publication Critical patent/JP2019511536A/ja
Publication of JP2019511536A5 publication Critical patent/JP2019511536A5/ja
Priority to JP2021170184A priority Critical patent/JP7341203B2/ja
Application granted granted Critical
Publication of JP6980694B2 publication Critical patent/JP6980694B2/ja
Priority to JP2023138999A priority patent/JP2023155365A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018553923A 2016-04-13 2017-04-13 投与のための方法およびレシニフェラトキシンで心血管疾患を治療する方法 Active JP6980694B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021170184A JP7341203B2 (ja) 2016-04-13 2021-10-18 投与のための方法およびレシニフェラトキシンで心血管疾患を治療する方法
JP2023138999A JP2023155365A (ja) 2016-04-13 2023-08-29 投与のための方法およびレシニフェラトキシンで心血管疾患を治療する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662322079P 2016-04-13 2016-04-13
US62/322,079 2016-04-13
PCT/US2017/027480 WO2017180907A1 (en) 2016-04-13 2017-04-13 Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021170184A Division JP7341203B2 (ja) 2016-04-13 2021-10-18 投与のための方法およびレシニフェラトキシンで心血管疾患を治療する方法

Publications (3)

Publication Number Publication Date
JP2019511536A JP2019511536A (ja) 2019-04-25
JP2019511536A5 JP2019511536A5 (enExample) 2020-05-14
JP6980694B2 true JP6980694B2 (ja) 2021-12-15

Family

ID=60039929

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018553923A Active JP6980694B2 (ja) 2016-04-13 2017-04-13 投与のための方法およびレシニフェラトキシンで心血管疾患を治療する方法
JP2021170184A Active JP7341203B2 (ja) 2016-04-13 2021-10-18 投与のための方法およびレシニフェラトキシンで心血管疾患を治療する方法
JP2023138999A Pending JP2023155365A (ja) 2016-04-13 2023-08-29 投与のための方法およびレシニフェラトキシンで心血管疾患を治療する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021170184A Active JP7341203B2 (ja) 2016-04-13 2021-10-18 投与のための方法およびレシニフェラトキシンで心血管疾患を治療する方法
JP2023138999A Pending JP2023155365A (ja) 2016-04-13 2023-08-29 投与のための方法およびレシニフェラトキシンで心血管疾患を治療する方法

Country Status (8)

Country Link
US (3) US20170296506A1 (enExample)
EP (1) EP3442523A4 (enExample)
JP (3) JP6980694B2 (enExample)
KR (2) KR102395342B1 (enExample)
CN (2) CN120114438A (enExample)
AU (1) AU2017248665B2 (enExample)
IL (2) IL262328B2 (enExample)
WO (1) WO2017180907A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113490745A (zh) 2018-12-21 2021-10-08 索伦托药业有限公司 神经周施用树脂毒素治疗适应不良性疼痛
WO2020154261A1 (en) 2019-01-22 2020-07-30 Sorrento Therapeutics, Inc. Method for treating osteoarthritis pain by administering resiniferatoxin
CN116744867A (zh) * 2020-08-11 2023-09-12 索伦托药业有限公司 通过神经消融治疗肺部炎性疾病
WO2022245791A1 (en) * 2021-05-18 2022-11-24 Sorrento Therapeutics, Inc. Presurgical perineural administration of resiniferatoxin for reduction of post-operative pain

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211230D0 (en) * 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
CA2607219A1 (en) * 2005-05-18 2007-02-15 Neuraxon, Inc. Substituted benzimidazole compounds with dual nos inhibitory activity and mu opioid agonist activity
SI1976521T1 (sl) * 2006-01-25 2015-06-30 Insys Therapeutics, Inc. Podjezično fentanilno pršilo
EP2007376B1 (en) * 2006-03-13 2013-05-08 Hadasit Medical Research Services And Development Ltd. Therapeutic uses of cannabidiol compounds
CN101522181A (zh) * 2006-10-04 2009-09-02 纽若科伊公司 诱导低体温药物在治疗局部缺血的应用
CN101951937A (zh) * 2007-12-21 2011-01-19 赫尔辛医疗股份公司 使用伊帕瑞林刺激胃肠系统动力的方法
US8846324B2 (en) * 2010-10-06 2014-09-30 Celltrend Gmbh In vitro method for diagnosing or predicting hypertension and/or early-stage cardiovascular end-organ damage by determining the concentration of soluble prorenin receptor
MX368865B (es) * 2013-09-17 2019-08-02 Vectus Biosystems Ltd Composiciones para el tratamiento de hipertension y/o fibrosis.
US9956166B2 (en) 2013-09-18 2018-05-01 Sorrento Therapeutics, Inc. Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin

Also Published As

Publication number Publication date
IL298314B1 (en) 2024-12-01
JP7341203B2 (ja) 2023-09-08
CA3020815A1 (en) 2017-10-19
IL262328B (en) 2022-12-01
US20250082605A1 (en) 2025-03-13
EP3442523A1 (en) 2019-02-20
IL298314B2 (en) 2025-04-01
KR20190029511A (ko) 2019-03-20
KR102508022B1 (ko) 2023-03-10
IL298314A (en) 2023-01-01
KR102395342B1 (ko) 2022-05-10
IL262328A (en) 2018-11-29
AU2017248665A1 (en) 2018-11-08
JP2022001608A (ja) 2022-01-06
US20220000837A1 (en) 2022-01-06
CN109562096A (zh) 2019-04-02
EP3442523A4 (en) 2019-12-04
IL262328B2 (en) 2023-04-01
KR20220062667A (ko) 2022-05-17
JP2023155365A (ja) 2023-10-20
CN120114438A (zh) 2025-06-10
US20170296506A1 (en) 2017-10-19
WO2017180907A1 (en) 2017-10-19
JP2019511536A (ja) 2019-04-25
AU2017248665B2 (en) 2023-01-05

Similar Documents

Publication Publication Date Title
JP7341203B2 (ja) 投与のための方法およびレシニフェラトキシンで心血管疾患を治療する方法
Benedetti et al. Control of postoperative pain by transcutaneous electrical nerve stimulation after thoracic operations
Agrawal et al. Effect of intrathecal midazolam bupivacaine combination on post operative analgesia
Issa et al. Intrathecal clonidine reduces the incidence of ischemia-provoked ventricular arrhythmias in a canine postinfarction heart failure model
JP2620642B2 (ja) 麻薬性鎮痛剤とベンゾジアゼピンとを組み合わせて非経口投与した後に観察される平均血圧の低下を拮抗させるための医薬品
CA3020815C (en) Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
Baranidharan et al. Implantable technology for pain management
Gordin et al. Acute and chronic pain management in palliative care
Cherry et al. Management of chronic intractable angina–spinal opioids offer an alternative therapy
Royal Resiniferatoxin for permanent pain relief in cancer patients
Costa et al. Microneurographic evidence of sudden sympathetic withdrawal in carotid sinus syncope; treatment with ergotamine
Dasta Local anesthetics: evolving to a new standard of care
Camci et al. Implantable cardioverter-defibrillator placement in patients with mild-to-moderate left ventricular dysfunction: hemodynamics and recovery profile with two different anesthetics used during deep sedation
Sakura et al. Using ultrasound guidance in peripheral nerve blocks
EP1762239B1 (en) Lofexidine for intraspinal administration
Staudt et al. Neuromodulation for Non-urologic Chronic Pain
Baranidharan et al. Implantable technology for pain management
WO2022175973A1 (en) An injectable composition for long term delivery of nalbuphine or nalbuphine ester prodrug or its salts and use thereof
US20070060632A1 (en) Lofexidine
Shalaby Ahmed Adel Abd El Fattah El beleehy
Yung et al. Neostigmine as the Cause of Cardiac Arrest After Elective Total Knee Arthroplasty (TKA) in a Healthy Man
Huh Spinal cord stimulation for managing angina from coronary artery disease
Khandagale et al. A REVIEW ON LOCAL ANESTHETIC SUSTAINED-RELEASE PAIN MANAGEMENT
Hassenbusch Medical Management Versus Interventional Therapeutic Options
Hassenbusch Cancer Pain

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200402

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200402

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20201126

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20201127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210521

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211018

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211101

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211117

R150 Certificate of patent or registration of utility model

Ref document number: 6980694

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250